Skip to main content
SpringerLink
Log in

Comment on: “Monoamine Oxidase Inhibitors (MAOIs) in Psychiatric Practice: How to Use them Safely and Effectively”

  • Letter to the Editor
  • Published:
CNS Drugs Aims and scope Submit manuscript

A Letter to the Editor to this article was published on 07 December 2021

The Original Article was published on 09 July 2021

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Chamberlain SR, Baldwin DS. Monoamine oxidase inhibitors (MAOIs) in psychiatric practice: how to use them safely and effectively. CNS Drugs. 2021;35(7):703–16.

    Article  CAS  Google Scholar 

  2. Tan DX, Manchester LC, Esteban-Zubero E, Zhou Z, Reiter RJ. Melatonin as a potent and inducible endogenous antioxidant: synthesis and metabolism. Molecules. 2015;20(10):18886–906.

    Article  CAS  Google Scholar 

  3. Tordjman S, Chokron S, Delorme R, Charrier A, Bellissant E, Jaafari N, et al. Melatonin: pharmacology, functions and therapeutic benefits. Curr Neuropharmacol. 2017;15(3):434–43.

    Article  CAS  Google Scholar 

  4. Youdim MB, Edmondson D, Tipton KF. The therapeutic potential of monoamine oxidase inhibitors. Nat Rev Neurosci. 2006;7(4):295–309.

    Article  CAS  Google Scholar 

  5. Edmondson DE, Binda C, Wang J, Upadhyay AK, Mattevi A. Molecular and mechanistic properties of the membrane-bound mitochondrial monoamine oxidases. Biochemistry. 2009;48(20):4220–30.

    Article  CAS  Google Scholar 

  6. Tipton KF, Boyce S, O’Sullivan J, Davey GP, Healy J. Monoamine oxidases: certainties and uncertainties. Curr Med Chem. 2004;11(15):1965–82.

    Article  CAS  Google Scholar 

  7. Pletscher A, Gey KF, Zeller P. Monoaminoxidaseinhibitoren. Fortschr Arzneimittelforsch. 1960;2:417–590.

    CAS  PubMed  Google Scholar 

  8. Shulman KI, Herrmann N, Walker SE. Current place of monoamine oxidase inhibitors in the treatment of depression. CNS Drugs. 2013;27(10):789–97.

    Article  CAS  Google Scholar 

  9. Kalgutkar AS, Dalvie DK, Castagnoli N Jr, Taylor TJ. Interactions of nitrogen-containing xenobiotics with monoamine oxidase (MAO) isozymes A and B: SAR studies on MAO substrates and inhibitors. Chem Res Toxicol. 2001;14(9):1139–62.

    Article  CAS  Google Scholar 

  10. Kopin IJ, Pare CM, Axelrod J, Weissbach H. The fate of melatonin in animals. J Biol Chem. 1961;236:3072–5.

    Article  CAS  Google Scholar 

  11. Kveder S, McIsaac WM. The metabolism of melatonin (N-acetyl-5-methoxytryptamine) and 5-methoxytryptamine. J Biol Chem. 1961;236:3214–20.

    Article  CAS  Google Scholar 

  12. Oxenkrug GF, Balon R, Jain AK, McIntyre IM. Melatonin plasma response to MAO inhibitor: influence on human pineal activity? Acta Psychiatr Scand. 1988;77(2):160–2.

    Article  CAS  Google Scholar 

  13. Ricken R, Ulrich S, Schlattmann P, Adli M. Tranylcypromine in mind (Part II): review of clinical pharmacology and meta-analysis of controlled studies in depression. Eur Neuropsychopharmacol. 2017;27(8):714–31.

    Article  CAS  Google Scholar 

  14. Bass C, Kerkwin R. Rediscovering monoamine oxidase inhibitors: benefits underestimated, side effects exaggerated. BMJ. 1989;298:345–6.

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Medical-Scientific Department, Aristo Pharma GmbH, Wallenroder Straße 8-10, 13435, Berlin, Germany

    Sven Ulrich

Authors
  1. Sven Ulrich
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Sven Ulrich.

Ethics declarations

Funding

No funding was received for the preparation of this letter.

Conflict of interest

Sven Ulrich is an employee of Aristo Pharma GmbH. Aristo Pharma GmbH is marketing a tranylcypromine drug product.

Ethics approval

Not applicable.

Consent to participate

Not applicable.

Consent for publication

Not applicable.

Availability of Data and Material

Not available.

Code Availability

Not available.

Author contributions

Sven Ulrich wrote the letter, submitted it to the journal, and takes responsibility for its contents.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Ulrich, S. Comment on: “Monoamine Oxidase Inhibitors (MAOIs) in Psychiatric Practice: How to Use them Safely and Effectively”. CNS Drugs 36, 101–102 (2022). https://doi.org/10.1007/s40263-021-00881-2

Download citation

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40263-021-00881-2

Search

Navigation